BioIntellisense has developed a clinical device for continuous health monitoring, predictive analytics, and algorithmic insights. Their device provides medical-grade monitoring through sensor-enabled wearable technology that performs advanced analytics for early detection of skin temperature, heart rate, respiratory rate, fall detection, coughing, sneezing, and vomiting frequency. This real-time data is channeled to their platform, enabling hospitals to assess vital signs, physiological biometrics, and symptomatic events in patients.

Investors Include:

Chimera Capital, Dexcom Ventures, Mary Tolan, University of Colorado Health, Pendrell, Philips, iD Ventures America, TT Capital Partners, Fresenius Medical Care, Royal Philips Electronics (Restoratives and Impression Portfolios), CU Healthcare Innovation Fund, Philips Ventures, Fresenius Medical Care Ventures, Skypoint Ventures, United States Army, James Murren, TLG Capital Management, Jonathan Weiner.

Collective explained in 2 minutes

Learn how Collective's solutions enable you to manage your risk and maximize your wealth

Learn more

Our available services for this company

Lifetime IncomeCharitable Remainder Trust

Tax SavingsDonor Advised Fund